bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating restated by analysts at Jefferies Group LLC in a report released on Thursday.
A number of other research analysts have also weighed in on BLUE. Zacks Investment Research lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday, April 25th. BTIG Research reaffirmed a “buy” rating on shares of bluebird bio in a research note on Monday, May 1st. Maxim Group reaffirmed a “hold” rating on shares of bluebird bio in a research note on Friday, May 5th. Morgan Stanley raised their price target on shares of bluebird bio from $87.00 to $91.00 and gave the company an “equal weight” rating in a research note on Monday, May 8th. Finally, Standpoint Research started coverage on shares of bluebird bio in a research note on Tuesday, May 30th. They issued a “buy” rating and a $110.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the stock. bluebird bio currently has an average rating of “Buy” and a consensus target price of $100.14.
Shares of bluebird bio (NASDAQ:BLUE) opened at 99.80 on Thursday. The stock’s market capitalization is $4.09 billion. The company has a 50 day moving average price of $97.43 and a 200-day moving average price of $83.86. bluebird bio has a 52-week low of $37.05 and a 52-week high of $123.75.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.76) by $0.08. The firm had revenue of $6.83 million for the quarter, compared to analyst estimates of $1.51 million. bluebird bio had a negative net margin of 2,402.03% and a negative return on equity of 35.17%. On average, analysts predict that bluebird bio will post ($6.72) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.wkrb13.com/markets/2284085/jefferies-group-llc-reiterates-buy-rating-for-bluebird-bio-inc-nasdaqblue.html.
In other news, Director Daniel Lynch sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $90.01, for a total transaction of $90,010.00. Following the completion of the sale, the director now owns 2,400 shares in the company, valued at approximately $216,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Philip D. Gregory sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $99.04, for a total transaction of $148,560.00. Following the sale, the insider now owns 37,279 shares of the company’s stock, valued at approximately $3,692,112.16. The disclosure for this sale can be found here. Insiders have sold a total of 70,295 shares of company stock valued at $7,320,577 in the last 90 days. Insiders own 3.90% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new stake in shares of bluebird bio during the fourth quarter worth about $1,477,000. FMR LLC increased its stake in shares of bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock worth $556,918,000 after buying an additional 37,742 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of bluebird bio during the first quarter worth about $858,000. Macquarie Group Ltd. purchased a new stake in shares of bluebird bio during the fourth quarter worth about $703,000. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of bluebird bio by 7.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 28,505 shares of the biotechnology company’s stock worth $1,759,000 after buying an additional 2,017 shares in the last quarter.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284085/jefferies-group-llc-reiterates-buy-rating-for-bluebird-bio-inc-nasdaqblue.html
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.